Business
Enanta Pharmaceuticals Announces the Appointment of Mark G. Foletta to Its Board of Directors
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Mark G. Foletta to its Board of Directors. Mr. Foletta will also serve as the Chair of the Audit Committee and will be a member of the Nominating and Corporate Governance Committee. The appointment of Mr. Foletta increases the number of Enanta Directors to seven.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005071/en/Enanta Pharmaceuticals Announces the Appointment of Mark G. Foletta to its Board of Directors (Photo: Business Wire)\n\n“We are pleased to welcome Mark to our Board during an important time in Enanta’s growth,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Mark’s extensive financial, operational and governance leadership will be invaluable as we continue to develop our broad pipeline of small molecule drugs for viral infections and liver diseases.”\n\n\n“Enanta is well-positioned for enduring success in advancing its virology and liver disease treatments,” said Mr. Foletta. “I look forward to collaborating with the leadership team and members of the Board to further Enanta’s mission and bring these critical therapies to patients in need.”\n\n\nMr. Foletta brings to Enanta more than 25 years of experience in financial, operational and governance leadership roles in the pharmaceutical and biotechnology industry. Most recently, he was Executive Vice President and Chief Financial Officer of Tocagen, a clinical-stage biopharmaceutical company focused on advancing a cancer-selective gene therapy platform, prior to its merger with Forte Biosciences. Prior to Tocagen, Mr. Foletta was Chief Financial Officer of Biocept, Inc. and served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., where he helped drive the evolution of the company from a research and development organization to a fully integrated biopharmaceutical company. Mr. Foletta has held other management positions including Senior Vice President, Chief Financial Officer and Corporate Secretary of Intermark, Inc. and Triton Group Ltd. Earlier in his career he worked a...